Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

K. Amiri



Author of

  • +

    P2.03a - Poster Session with Presenters Present (ID 464)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P2.03a-039 - ABOUND.70+: Interim Quality of Life (QoL) Results of nab-Paclitaxel/Carboplatin Treatment of Elderly Patients With NSCLC (ID 4286)

      14:30 - 14:30  |  Author(s): K. Amiri

      • Abstract

      Background:
      QoL data in elderly patients with NSCLC receiving chemotherapy are limited, although these assessments can help inform treatment decisions. Interim QoL outcomes from the ongoing ABOUND.70+ study are reported here.

      Methods:
      Patients aged ≥ 70 years with locally advanced/metastatic NSCLC were randomized 1:1 to first-line nab-paclitaxel 100 mg/m[2] on days 1, 8, and 15 + carboplatin AUC 6 on day 1 every 21 days or the same nab-paclitaxel/carboplatin regimen with a 1-week break between cycles. The primary endpoint is the percentage of patients with grade ≥ 2 peripheral neuropathy or grade ≥ 3 myelosuppression adverse events. QoL (an exploratory endpoint) was assessed on day 1 of each cycle using the Lung Cancer Symptom Scale (LCSS) and EuroQoL-5 Dimensions-5 Levels (EQ-5D-5L).

      Results:
      This analysis included 119 patients; 88 patients (74%) completed baseline + ≥ 1 postbaseline QoL assessments. The median age was 76 years (range, 70-93 years); 30% of patients were ≥ 80 years of age, 56% were male, and 99% had an ECOG PS 0-1. In general, LCSS symptom burden index and average total scores improved during cycles 1-4. The LCSS item of cough improved each cycle, with a mean change of 18.98 mm from baseline to end of cycle 4 on the visual analog scale (VAS; 95% CI, 8.42-29.54 mm). Fifty percent of patients had a clinically meaningful improvement (≥ 10 mm [VAS]) from baseline in the composite LCSS pulmonary symptom items of cough, shortness of breath, and hemoptysis. More than 80% of patients maintained/improved in each EQ-5D-5L dimension from baseline; complete resolution of baseline pain/discomfort, anxiety/depression, and self-care items was reported by ≥ 55% of patients (Table). Figure 1



      Conclusion:
      Clinically meaningful improvements in several QoL dimensions were observed in elderly patients with NSCLC treated with nab-paclitaxel/carboplatin. These data support the role of nab-paclitaxel/carboplatin in this patient population. NCT02151149